Chicago Equity Partners’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
$1.76M Buy
98,120
+40,995
+72% +$778K 0.18% 162
2019
Q4
$1.01M Buy
57,125
+25,610
+81% +$444K 0.06% 456
2019
Q3
$489K Hold
31,515
0.02% 689
2019
Q2
$541K Hold
31,515
0.02% 687
2019
Q1
$507K Sell
31,515
-47,475
-60% -$769K 0.02% 670
2018
Q4
$1.16M Buy
78,990
+15,790
+25% +$252K 0.05% 461
2018
Q3
$1.15M Sell
63,200
-9,905
-14% -$174K 0.03% 503
2018
Q2
$1.23M Sell
73,105
-162,155
-69% -$3.07M 0.04% 480
2018
Q1
$4.61M Buy
235,260
+6,820
+3% +$132K 0.15% 199
2017
Q4
$4.63M Buy
228,440
+24,845
+12% +$457K 0.14% 209
2017
Q3
$3.54M Sell
203,595
-111,845
-35% -$1.51M 0.11% 260
2017
Q2
$4.04M Buy
315,440
+145,410
+86% +$1.94M 0.11% 228
2017
Q1
$2.2M Buy
170,030
+2,770
+2% +$35K 0.06% 298
2016
Q4
$1.65M Buy
167,260
+83,170
+99% +$911K 0.04% 371
2016
Q3
$1.02M Buy
+84,090
New +$859K 0.03% 427
2014
Q2
Sell
-12,625
Closed -$160K 471
2014
Q1
$160K Sell
12,625
-525
-4% -$7.79K ﹤0.01% 436
2013
Q4
$197K Buy
+13,150
New +$169K 0.01% 401

Other funds holding HALO

Chicago Equity Partners's HALO Position: Q1 2020 in Review

Chicago Equity Partners increased its Halozyme (HALO) stake by 72% in Q1 2020, buying an estimated $778K and bringing the position to 98,120 shares worth $1.76M. The position accounts for 0.18% of the portfolio, ranked #162.

Chicago Equity Partners first reported a position in HALO in Q4 2013 and has held it in 17 quarters since. The position peaked at $4.63M in Q4 2017. 209 funds tracked by Wall St. Rank hold HALO as of Q1 2020.

  • Chicago Equity Partners held 98,120 shares of Halozyme worth $1.76M as of Q1 2020.
  • Chicago Equity Partners bought 40,995 Halozyme shares in Q1 2020, an estimated $778K.
  • Halozyme made up 0.18% of Chicago Equity Partners's portfolio in Q1 2020, its #162 holding.
  • Chicago Equity Partners first reported a position in Halozyme in Q4 2013 and has held it in 17 quarters since.
  • Chicago Equity Partners's Halozyme position peaked at $4.63M in Q4 2017.
  • 209 funds tracked by Wall St. Rank held Halozyme as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.